Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.49 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.49 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | VCAM1 | P19320 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.43 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6573505 | 0.93 | KMT2A (0.53) | CYP3A4MAPTBLMPMP22KMT2A | |
| SCHEMBL4511665 | 0.91 | KMT2A (0.54) | CYP3A4MAPTBLMPMP22KMT2A | |
| SCHEMBL8597606 | 0.91 | KMT2A (0.54) | CYP3A4MAPTBLMPMP22KMT2A | |
| SCHEMBL27686809 | 0.89 | KMT2A (0.57) | CYP3A4MAPTBLMPMP22KMT2A | |
| SCHEMBL6811571 | 0.86 | KMT2A (0.50) | CYP3A4MAPTBLMPMP22KMT2A | |
| SCHEMBL6814702 | 0.86 | ALDH1A1 (0.62) | CYP3A4MAPTBLMPMP22KMT2A | |
| SCHEMBL16117987 | 0.84 | CYP3A4 (0.49) | CYP3A4MAPTBLMPMP22KMT2A | |
| SCHEMBL2977714 | 0.83 | DTYMK (0.50) | CYP3A4MAPTKMT2AALDH1A1SLC9A1 | |
| SCHEMBL6570778 | 0.83 | VCAM1 (0.49) | CYP3A4MAPTBLMPMP22KMT2A | |
| SCHEMBL29596737 | 0.83 | DTYMK (0.50) | CYP3A4MAPTKMT2AALDH1A1SLC9A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121091-A1 | Processes of preparing asymmetric dinitrobenzamide mustard compounds, intermediate compounds useful therein and products obtained therefrom | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-05-13 | — | — | US | disclosed |
| US-20100121091-A1 | Processes of preparing asymmetric dinitrobenzamide mustard compounds, intermediate compounds useful therein and products obtained therefrom | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-05-13 | — | — | US | disclosed |
| US-20100121091-A1 | Processes of preparing asymmetric dinitrobenzamide mustard compounds, intermediate compounds useful therein and products obtained therefrom | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-05-13 | — | — | US | disclosed |
| WO-2009127815-A1 | AMINOALYL-IMIDAZOTETRAZINES FOR TREATMENT OF CANCER | THE UNIVERSITY OF BRADFORD (GB) | 2009-10-22 | — | — | WO | disclosed |
| EP-2059499-A1 | PROCESSES OF PREPARING ASYMMETRIC DINITROBENZAMIDE MUSTARD COMPOUNDS, INTERMEDIATE COMPOUNDS USEFUL THEREIN AND PRODUCTS OBTAINED THEREFROM | Auckland Uniservices Limited (NZ) | 2009-05-20 | — | — | EP | disclosed |
| WO-2008030112-A1 | PROCESSES OF PREPARING ASYMMETRIC DINITROBENZAMIDE MUSTARD COMPOUNDS, INTERMEDIATE COMPOUNDS USEFUL THEREIN AND PRODUCTS OBTAINED THEREFROM | AUCKLAND UNISERVICES LIMITED (NZ) | 2008-03-13 | — | — | WO | disclosed |
| WO-2008030112-A1 | PROCESSES OF PREPARING ASYMMETRIC DINITROBENZAMIDE MUSTARD COMPOUNDS, INTERMEDIATE COMPOUNDS USEFUL THEREIN AND PRODUCTS OBTAINED THEREFROM | AUCKLAND UNISERVICES LIMITED (NZ) | 2008-03-13 | — | — | WO | disclosed |
| EP-0638123-B1 | BACTERIAL NITROREDUCTASE FOR THE REDUCTION OF CB 1954 AND ANALOGUES THEREOF TO A CYTOTOXIC FORM | CANCER REC TECH LTD (GB) | 2006-12-27 | — | — | EP | disclosed |
| EP-0725826-B1 | IMPROVEMENTS RELATING TO CANCER THERAPY | CANCER RES CAMPAIGN TECH (GB) | 2005-01-26 | — | — | EP | disclosed |
| CN-1137100-C | Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family | ��ʲ | 2004-02-04 | — | — | CN | disclosed |
| US-5633158-A | CULTURE PRODUCT; GENETIC ENGINEERING | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1997-05-27 | — | — | US | disclosed |
| CN-1139430-A | Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family | WARNER LAMBERT CO (US) | 1997-01-01 | — | — | CN | disclosed |
| EP-0741711-A1 | TRICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY | WARNER-LAMBERT COMPANY (US) | 1996-11-13 | — | — | EP | disclosed |
| EP-0725826-A1 | IMPROVEMENTS RELATING TO CANCER THERAPY | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-08-14 | — | — | EP | disclosed |
| WO-1996014420-A1 | INDUCIBLE CELL ABLATION | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-05-17 | — | — | WO | disclosed |
| WO-1995019970-A1 | TRICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY | WARNER-LAMBERT COMPANY (US) | 1995-07-27 | — | — | WO | disclosed |
| WO-1995012678-A2 | IMPROVEMENTS RELATING TO CANCER THERAPY | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1995-05-11 | — | — | WO | disclosed |
| EP-0638123-A1 | BACTERIAL NITROREDUCTASE FOR THE REDUCTION OF CB 1954 AND ANALOGUES THEREOF TO A CYTOTOXIC FORM | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1995-02-15 | — | — | EP | disclosed |
| EP-0540263-A1 | Bacterial nitroreductase for the reduction of CB 1954 and analogues thereof to a cytotoxic form | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1993-05-05 | — | — | EP | disclosed |
| WO-1993008288-A1 | BACTERIAL NITROREDUCTASE FOR THE REDUCTION OF CB 1954 AND ANALOGUES THEREOF TO A CYTOTOXIC FORM | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1993-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121091-A1 | Processes of preparing asymmetric dinitrobenzamide mustard compounds, intermediate compounds useful therein and products obtained therefrom | HRH2, HRH4, H1-2 | CYP3A4 782/4885MAPT 4882/4885BLM 3953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.